Synonyms: ANB-011 | dostarlimab-gxly | Jemperli® | TSR-042 | WBP-285
dostarlimab is an approved drug (EMA & FDA (2021))
Compound class:
Antibody
Comment: Dostarlimab is a humanized, IgG4κ programmed cell death 1 (PD-1) blocking monoclonal antibody from GlaxoSmithKline.
|
Classification ![]() |
|
Compound class | Antibody |
Ligand families/groups | Immune checkpoint modulators |
Approved drug? | Yes (EMA & FDA (2021)) |
Approved drug? | Yes. FDA (2021) | EMA (2021) |
International Nonproprietary Names ![]() |
|
INN number | INN |
10787 | dostarlimab |
Synonyms ![]() |
ANB-011 | dostarlimab-gxly | Jemperli® | TSR-042 | WBP-285 |
Database Links ![]() |
|
Specialist databases | |
IMGT/mAb-DB | 849 |
Other databases | |
GtoPdb PubChem SID | 441604890 |
Search PubMed clinical trials | dostarlimab |
Search PubMed titles | dostarlimab |
Search PubMed titles/abstracts | dostarlimab |